Granted Patent
B2
US 12,258,397 · App. 17/096,138 · Granted Mar 25, 2025
Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection
Inventors:
Michael C. Jensen (Bainbridge Island, WA); Suzie Pun (Seattle, WA); Nataly Kacherovsky (Seattle, WA)
C07K16/2803A61K35/28A61K38/1774A61K38/179A61K38/1793A61K39/3955A61K39/4611A61K39/4631A61K39/464412C07K14/7051C07K14/70517C07K14/70521C07K14/70578C07K14/71C07K14/7151C07K16/2818C07K16/32C12N5/0636C12N5/0638C12N9/12C12N15/85C12Y207/10001A61K2035/124A61K2039/505A61K2039/572C07K2317/14C07K2317/524C07K2317/526C07K2317/53C07K2317/622C07K2317/73C07K2319/02C07K2319/03C07K2319/33C12N2510/00C12N2800/90
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Aspects of the invention described herein include methods of treating, inhibiting, ameliorating and/or eliminating a virus or cancer cells in a subject utilizing genetically engineered human T-cells having receptors for a molecule presented by the virus or the cancer cells, wherein the genetically engineered T cells are isolated utilizing a two-stage MTX selection that employs increasing concentrations of MTX.
Claims (29)
1. A method of generating engineered multiplexed T-cells for adoptive T-cell immunotherapy comprising:
(a) introducing into a population of T-cells a first minicircle and a second minicircle to obtain a first population of transfected T-cells, wherein each minicircle comprises a gene delivery polynucleotide, wherein the gene delivery polynucleotide comprises:
(i) a first inverted terminal repeat (ITR),
(ii) a promoter,
(iii) a nucleic acid encoding a polypeptide, wherein the polypeptide of the first minicircle is different from the polypeptide of the second minicircle,
(iv) a nucleic acid encoding a double mutant of dihydrofolate reductase (DHFR) comprising the nucleotide sequence as set forth in SEQ ID NO:2,
(v) a second ITR,
wherein (i) to (v) have a 5′ to 3′ order in the gene delivery polynucleotide;
(b) introducing a vector encoding a Sleeping Beauty transposase into the first population of transfected T-cells to obtain a second population of transfected T-cells;
(c) selecting for T-cells comprising the first minicircle and the second minicircle in the second population of transfected T-cells, wherein the selecting comprises a first round of selection comprising contacting the second population of transfected T-cells with methotrexate at a first concentration range, and a second round of selection comprising contacting the second population of transfected T-cells with methotrexate at a second concentration range, wherein the second concentration range is at least 1.5 fold higher than that of the first concentration range; and
(d) isolating the selected T-cells, wherein at least 75% of the selected T-cells express both (a) the polypeptide of the first minicircle, and (b) the polypeptide of the second minicircle.
2. The method of claim 1 , further comprising obtaining each minicircle by:
(i) providing a plasmid comprising an attP attachment site (attP), an attB attachment site (attB), and the gene delivery polynucleotide, wherein the gene delivery polynucleotide is located between the attP and the attB, and
(ii) inducing site-specific recombination in the plasmid, thereby obtaining the first minicircle or the second minicircle.
3. The method of claim 1 , wherein expression of the of the polypeptide of the first minicircle and the polypeptide of the second minicircle gene delivery polynucleotide in the isolated T-cells persists after withdrawal of the methotrexate for at least 2 weeks.
4. The method of claim 3 , further comprising measuring expression in the isolated T-cells of the polypeptide of the first minicircle and the polypeptide of the second minicircle at least 2 weeks after withdrawal of the methotrexate.
5. The method of claim 1 , wherein the first concentration range is 50 nM-100 nM and the second concentration range is 75 nM to 150 nM.
6. The method of claim 1 , wherein the first concentration range is 75 nM-150 nM and the second concentration range is 112.5 nM to 225 nM.
7. The method of claim 1 , wherein the first concentration range is 300 nM-675 nM and the second concentration range is 450 nM to 1012 nM.
8. The method of claim 1 , wherein the first round of selection comprises contacting the second population of transfected T-cells to the methotrexate at the first concentration range for at least 2 days before the second round of selection.
9. The method of claim 1 , wherein the second round of selection comprises contacting the second population of transfected T-cells to the methotrexate at the second concentration range for at least 2 days.
10. The method of claim 1 , wherein the promoter is an EF1 promoter.
11. The method of claim 1 , wherein the first ITR and the second ITR are each derived from a Sleeping Beauty transposon.
12. The method of claim 1 , wherein the nucleic acid encoding a polypeptide is codon optimized for expression in a human.
13. The method of claim 1 , wherein the polypeptide comprises a chimeric antigen receptor (CAR).
14. The method of claim 13 , wherein the CAR comprises an anti-CD19 CAR.
15. The method of claim 1 , wherein the population of T-cells comprises a cell selected from the group consisting of a CD4+ T-cell, a CD8+ T-cell, a precursor T-cell, and a hematopoietic stem cell.
16. The method of claim 1 , further comprising administering the isolated T-cells to a subject.
17. The method of claim 16 , wherein the subject is human.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 24, 2021
From: PUN, SUZIE; KACHEROVSKY, NATALY
To: UNIVERSITY OF WASHINGTON
Reel/Frame 056332/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 24, 2021
From: JENSEN, MICHAEL C.
To: SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE)
Reel/Frame 056332/0402 →
Continuity (8)
Division
15302449
Provisional Application
62090845
· Dec 11, 2014
Provisional Application
62089730
· Dec 9, 2014
Provisional Application
62088363
· Dec 5, 2014
Provisional Application
62058973
· Oct 2, 2014
Provisional Application
61986479
· Apr 30, 2014
Provisional Application
61977751
· Apr 10, 2014
References Cited (286)
US 5783186A
· Arakawa et al.
· 1998
[cited by applicant]
US 6040177A
· Riddell et al.
· 2000
[cited by applicant]
US 6133027A
· Yee et al.
· 2000
[cited by applicant]
US 7070995B2
· Jensen
· 2006
[cited by applicant]
US 7446179B2
· Jensen et al.
· 2008
[cited by applicant]
US 7709253B2
· Gambhir et al.
· 2010
[cited by applicant]
US 7910101B2
· Cunningham et al.
· 2011
[cited by applicant]
US 8802374B2
· Jensen
· 2014
[cited by applicant]
US 8822647B2
· Jensen
· 2014
[cited by applicant]
US 8916381B1
· June et al.
· 2014
[cited by applicant]
US 8975071B1
· June et al.
· 2015
[cited by applicant]
US 9328156B2
· June et al.
· 2016
[cited by applicant]
US 9447194B2
· Jensen
· 2016
[cited by applicant]
US 9481728B2
· June et al.
· 2016
[cited by applicant]
US 9499629B2
· June et al.
· 2016
[cited by applicant]
US 9518123B2
· June et al.
· 2016
[cited by applicant]
US 9540445B2
· June et al.
· 2017
[cited by applicant]
US 9629877B2
· Cooper
· 2017
[cited by examiner]
US 9701758B2
· Cooper et al.
· 2017
[cited by applicant]
US 9856322B2
· Campana et al.
· 2018
[cited by applicant]
US 20020111474A1
· Capon et al.
· 2002
[cited by applicant]
US 20030148982A1
· Brenner et al.
· 2003
[cited by applicant]
US 20040037816A1
· Boyd
· 2004
[cited by applicant]
US 20050129671A1
· Cooper et al.
· 2005
[cited by applicant]
US 20060160090A1
· Anzures et al.
· 2006
[cited by applicant]
US 20070020237A1
· Yoon
· 2007
[cited by applicant]
US 20070087346A1
· Ciliberto et al.
· 2007
[cited by applicant]
US 20070166318A1
· Macina et al.
· 2007
[cited by applicant]
US 20080044413A1
· Hammond
· 2008
[cited by applicant]
US 20090098142A1
· Kasalan et al.
· 2009
[cited by applicant]
US 20120297493A1
· Cooper et al.
· 2012
[cited by applicant]
US 20130011394A1
· Knoetgen
· 2013
[cited by applicant]
US 20130071414A1
· Dotti et al.
· 2013
[cited by applicant]
US 20130143559A1
· Nishida et al.
· 2013
[cited by applicant]
US 20130280220A1
· Ahmed et al.
· 2013
[cited by applicant]
US 20140056868A1
· Zechiedrich et al.
· 2014
[cited by applicant]
US 20150038694A1
· Nicotra
· 2015
[cited by applicant]
US 20150329640A1
· Finer
· 2015
[cited by applicant]
US 20160017048A1
· Dotti et al.
· 2016
[cited by applicant]
US 20170015746A1
· Jensen
· 2017
[cited by applicant]
US 20170029774A1
· Jensen et al.
· 2017
[cited by applicant]
US 20170209543A9
· Jensen
· 2017
[cited by applicant]
US 20170224733A1
· Badie et al.
· 2017
[cited by applicant]
US 20210371517A1
· Jensen
· 2021
[cited by applicant]
US 20220411805A1
· Jensen
· 2022
[cited by applicant]
US 20230130938A1
· Jensen
· 2023
[cited by applicant]
CN 1809277
· 2006
[cited by applicant]
DE 102011118018
· 2013
[cited by applicant]
JP 2006518753
· 2006
[cited by applicant]
RU 2003129528A
· 2005
[cited by applicant]
WO WO9208796
· 1992
[cited by applicant]
WO WO9400143
· 1994
[cited by applicant]
WO WO9818923
· 1998
[cited by applicant]
WO WO0023573
· 2000
[cited by applicant]
WO WO01098506
· 2001
[cited by applicant]
WO WO0233101
· 2002
[cited by applicant]
WO WO02072605
· 2002
[cited by applicant]
WO WO02097099
· 2002
[cited by applicant]
WO WO03025228
· 2003
[cited by applicant]
WO WO03087338
· 2003
[cited by applicant]
WO WO04029284
· 2004
[cited by applicant]
WO WO05017102
· 2005
[cited by applicant]
WO WO05040212
· 2005
[cited by applicant]
WO WO05108617
· 2005
[cited by applicant]
WO WO07073499
· 2007
[cited by applicant]
WO WO07137267
· 2007
[cited by applicant]
WO WO08012237
· 2008
[cited by applicant]
WO WO09013359
· 2009
[cited by applicant]
WO WO09091826
· 2009
[cited by applicant]
WO WO10036986
· 2010
[cited by applicant]
WO WO10141543
· 2010
[cited by applicant]
WO WO11041093
· 2011
[cited by applicant]
WO WO11056894
· 2011
[cited by applicant]
WO WO12031744
· 2012
[cited by applicant]
WO WO12079000
· 2012
[cited by applicant]
WO WO12099973
· 2012
[cited by applicant]
WO WO12129514
· 2012
[cited by applicant]
WO WO12140130
· 2012
[cited by applicant]
WO WO12167192
· 2012
[cited by applicant]
WO WO13059593
· 2013
[cited by applicant]
WO WO13074916
· 2013
[cited by applicant]
WO WO13123061
· 2013
[cited by applicant]
WO WO13126733
· 2013
[cited by applicant]
WO WO13154760
· 2013
[cited by applicant]
WO WO13177533
· 2013
[cited by applicant]
WO WO13178635
· 2013
[cited by applicant]
WO WO14031687
· 2014
[cited by applicant]
WO WO14039044
· 2014
[cited by applicant]
WO WO14055657
· 2014
[cited by applicant]
WO WO14055668
· 2014
[cited by applicant]
WO WO14139672
· 2014
[cited by applicant]
WO WO14153270
· 2014
[cited by applicant]
WO WO15066551
· 2015
[cited by applicant]
WO WO15075468
· 2015
[cited by applicant]
WO WO15092024
· 2015
[cited by applicant]
WO WO15105522
· 2015
[cited by applicant]
WO WO15142675
· 2015
[cited by applicant]
WO WO15157399
· 2015
[cited by applicant]
WO WO15157432
· 2015
[cited by applicant]
Jonnalagadda et al., “Efficient Selection of Genetically Modified Human T Cells Using Methotrexate-Resistant Human Dihydrofolate Reductase”. Gene Ther. Aug. 2013 ;20(8):853-860. (Year: 2013).
[cited by examiner]
Kacherovsky et al., “Combination of Sleeping Beauty transposition and chemically induced dimerization selection for robust production of engineered cells”. Nucleic Acids Res. Jun. 2012 ;40(11):e85 (Year: 2012).
[cited by examiner]
Nakazawa et al., May 2009, 231. Expression of multiple transgenes in human T cells from PiggyBac transposons, Molecular Therapy, 17(Suppl 1):S91.
[cited by applicant]
Ahmed et al., “Regression of experimental medulloblastoma following transfer of HER2-specific T cells,” Cancer Res. (Jun. 15, 2007) 67(12):5957-64.
[cited by applicant]
Ahmed, Nabil, “CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM),” ClinicalTrials.gov Identifier: NCT01109095 (Apr. 22, 2010) pp. 1-8.
[cited by applicant]
Ahmed, Nabil, “Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,” ClinicalTrials.gov Identifier: NCT00902044 (May 14, 2009) pp. 1-11.
[cited by applicant]
Altschul et al., “Local Alignment Statistics, [27] Multiple Alignment and Phylogenetic Trees,” Methods in Enzymology (1996) 266:460-480.
[cited by applicant]
Bejcek et al. “Development and Characterization of Three Recombinant Single Chain Antibody Fragments (scFvs) Directed against the CD19 Antigen,” Cancer Res (1995) 55:2346-2351.
[cited by applicant]
Brentjens et al: “CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia”, Science Translational Medicine, 5(177), Mar. 20, 2013.
[cited by applicant]
Budde et al., “Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma”, PLoS One (2013) 8(12): e82742. https…
[cited by applicant]
Cartellieri et al., “A Novel Ex Vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells,” PLoS One (Apr. 3, 2014) vol. 9, No. 4, e93745, pp. 1-12.
[cited by applicant]
Cha et al., “IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo,” Breast Cancer Research and Treatment, Springer, NY, US (O…
[cited by applicant]
Chen et al., “Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin 7, and interleukin-15: Potential for adoptive T-cell immunotherapy,” Clinical Immunology (2006) v…
[cited by applicant]
Chen et al., “Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo”, Mol Ther. (2003) 8(3), 495-500.
[cited by applicant]
Chen et al: “Fusion Protein Linkers: Property, Design and Functionality”, Adv Drug Deliv Rev., Oct. 15, 2013; 65(10), pp. 1357-1369.
[cited by applicant]
Cho et al., “Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab”, Nature (Feb. 13, 2003) 421(6924):756-760.
[cited by applicant]
Converse et al: “Counterselection and Co-Delivery of Transposon and Transposase Functions for Sleeping Beauty-Mediated Transposition in Cultured Mammalian Cells”, Bioscience Reports, Kluwer Academic Publishers-Plenum Pu…
[cited by applicant]
Crewe et al., “Metabolism of Tamoxifen by recombinant human cytochrome P-450 enzymes: Formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen,”Drug Metab Dispos (…
[cited by applicant]
Database Geneseq [Online] May 5, 2005 (May 5, 2005 ), “Human splice variant protein expressed in ovary cells DEX0487 002.orf.4.”, XP002771301, retrieved from EBI accession No. GSP:ADY30515. Database accession No. ADY305…
[cited by applicant]
Database UniProt [Online] Oct. 3, 2012 (Oct. 3, 2012), “SubName: Full=Receptor tyrosine-protein kinase erbB-2 {ECO: 00003131Ensembl:ENSP00000464252}; Flags: Fragment;”, XP002771300, retrieved from EBI accession No. UNIP…
[cited by applicant]
Dotti, Gianpietro, et al. “Design and development of therapies using chimeric antigen recepto-expressing T cells.” Immunological reviews 257.1 (2014): 107-126.
[cited by applicant]
Ercikan-Abali et al., “Active Site-Directed Double Mutants of Dihydrofolate Reductase,” Cancer Res., (1996) vol. 56, No. 18, pp. 4142-4145.
[cited by applicant]
Gallinari et al., “A Functionally Orthogonal Estrogen Receptor-Based Transcription Switch Specifically Induced by a Nonsteroid Synthetic Ligand.” Chemistry and Biology (Aug. 1, 2005) vol. 12, No. 8, pp. 883-893.
[cited by applicant]
Gargett et al., “Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2,” Cytotherapy (2015) 17.4:…
[cited by applicant]
Garrett et al., “Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu,” The Journal of Immunology (Jun. 1, 2007) 178:7120-7131.
[cited by applicant]
Giry-Laterriere et al. “Polyswitch lentivectors: ‘all-in-one’ lentiviral vectors for drug-inducible gene expression, live selection, and recombination cloning,
[cited by applicant]
Godiska et al., “Linear plasmid vector for cloning of repetitive or unstable sequences in
[cited by applicant]
Gottschalk, Stephen, “Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy (HERCREEM)”, ClinicalTrials.gov Identifier: NCT00889954 (Apr. 29, 2009) pp. 1-9.
[cited by applicant]
Grada et al., “TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy”, Mol Ther Nucleic Acids, (Jul. 9, 2013) 2:e105. doi: 10.1038/mtna.2013.32.
[cited by applicant]
Han Weidong, “Treatment of Chemotherapy Refractory Human Epidermal growth Factor Receptor-2(HER-2) Positive Advanced Solid Tumors (CART-HER-2)”, (Sep. 5, 2013) ClinicalTrials.gov Identifier: NCT01935843, pp. 1-7.
[cited by applicant]
Holtkamp et al., “Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells,” Blood (Oct. 28, 2014), 2006/108:509-4017.
[cited by applicant]
Hong et al., “Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes,” J Immunotherapy (2014) vol. 37, No. 2, pp. 93-104.
[cited by applicant]
Hudecek et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T-cells. Clin Cancer Res. Jun. 15, 2013; 19(12): 3153-3164.
[cited by applicant]
Hudecek et al., Nov. 16, 2012, The Non-Signaling Extracellular Spacer Domain of CD19-Specific Chimeric Antigen Receptors Is Decisive for in Vivo Anti-Tumor Activity, Blood, 120(21):951, 3 pp.
[cited by applicant]
Huls et al., “First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor,” Blood (2013)…
[cited by applicant]
Jensen et al., “Designing chimeric antigen receptors to effectively and safely target tumors,” Curr Opin Immunol. (Apr. 2015) 33:9-15.
[cited by applicant]
Johansen et al., “Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS,” Gene Therapy (2002) 9:1291-1301.
[cited by applicant]
Johnston et al. “Regulated expression of erythropoietin from an AAV vector safely improves the anemia of beta-thalassemia in a mouse model,” Mol Ther. Apr. 1, 2003, 7(4):493-497.
[cited by applicant]
Jonnalagadda et al., “Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase,” Gene Therapy, vol. 20, No. 8, Jan. 10, 2013, pp. 853-860.
[cited by applicant]
Kacherovsky et al., “Combination of Sleeping Beauty transposition and chemically induced dimerization selection for robust production of engineered cells,” Nucleic Acids Research (2012) 49(11):e85.
[cited by applicant]
Kacherovsky et al., “Multiplexed 1-16 gene transfer to a human T-cell line by combining Sleeping Beauty transposon system with methotrexate selection”, Biotechnology and Bioengineering (Jul. 23, 2015) vol. 112, No. 7, p…
[cited by applicant]
Kay et al, “A robust system for production of minicircle DNA vectors”,12, Nov. 21, 2010, pp. 1287-1289.
[cited by applicant]
Klebanoff et al., “IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells,” PNAS (Feb. 17, 2004) vol. 101, No. 7, pp. 1969-1974.
[cited by applicant]
Kowolik et al., “CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells,” Cancer Res. (2006) 66(22):10995-1100…
[cited by applicant]
Kunkele et al., “Functional Tuning of CARs Reveals Signaling Threshold above which CD8+ CTL Antitumor Potency is Attenuated Due to Cell Fas-FasL-Dependent AICD,” Cancer Immunol Res. (Jan. 9, 2015) vol. 3, No. 4, pp. 368…
[cited by applicant]
Lemaigre et al., “Transcriptional control of genes that regulate glycolysis and gluconeogenesis in adult liver,” Biochem. J. (1994) 303:1-14.
[cited by applicant]
Leung et al., “Luminescent detection of DNA-binding proteins,” Nuc Acids Res (2012) 40(3): 941-955.
[cited by applicant]
Likar et al., “Using a mutated variant human deoxycytidine-kinase as a reporter gene for assessing adoptive T-cell therapy,” Questions hematology, oncology and immunopathology in pediatrics (2012) vol. 11, No. 2, pp. 23…
[cited by applicant]
Littlewood et al., “A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins,” Nucleic Acids Res (May 25, 1995) 23(10):1686-1690.
[cited by applicant]
Litvinova et al., “The influence of immunoregulatory cytokines IL-2, IL-7, and IL-15 upon activation, proliferation, and apoptosis of immune memory T-cells in vitro,” Cell and Tissue Biology (Dec. 11, 2013) vol. 7, No. …
[cited by applicant]
Loeken, Mary R., “Effects of mutation of the CREB binding site of the somatostatin promoter on cyclic AMP responsiveness in CV-1 cells”,
[cited by applicant]
Lupton et al., “Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene,” Mol Cell Biol. (Jun. 1991) 11(6):3374-3378.
[cited by applicant]
Maher, “Immunotherapy of Malignant Disease Using Chimeric Antigen Receptor Engrafted T Cells”,
[cited by applicant]
Mátés et al., “Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates,” Nature Genetics (Jun. 2009) vol. 41, No. 6, pp. 753-761.
[cited by applicant]
McGehee et al., “Differentiation-specific element: a cis-acting developmental switch required for the sustained transcriptional expression of the angiotensinogen gene during hormonal-induced differentiation of 3T3-L1 fi…
[cited by applicant]
Morgan et al., “Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2,” Mol Ther. (Apr. 2010) 18(4):843-51. doi: 10.1038/mt.2010.24.…
[cited by applicant]
O'Reilly et al., “Identification of an activating transcription factor (ATF) binding site in the human transforming growth factor-beta 2 promoter,” J. Biol. Chem. (Oct. 5, 1992) 267:19938-19943.
[cited by applicant]
Papapetrou et al. “Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras”, The Journal of clinical investigation. Ja…
[cited by applicant]
Park et al., “Adoptive Transfer of Chimeric Antigen Receptor Re-Directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma,” Mol. Ther. (Apr. 2007) vol. 15, No. 4; pp. 825-833.
[cited by applicant]
Pezutto et al., May 1, 1987, CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation, The Journal of Immunology, 138(9):2793-2799.
[cited by applicant]
Pollock et al. “Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector,” Proc Natl Acad Sci. USA Nov. 21, 2000, 97(24):13221-1326.
[cited by applicant]
Promega, “pSP64 Poly(A) Vector Sequence and Map,” Technical Bulletin No. 052, Revised May 2000, pp. 1-8.
[cited by applicant]
Riddell et al. “Adoptive therapy with chimeric antigen receptor modified T cells of defined subset composition.” Cancer journal (Sudbury, Mass. ) 20.2 (2014): 141-144.
[cited by applicant]
Riddell et al., “Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8+ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant. Fred Hutchinson Cancer R…
[cited by applicant]
Roscilli et al., “Long-term and tight control of gene expression in mouse skeletal muscle by a new hybrid human transcription factor,” Molecular Therapy (Nov. 2002) 1;6(5):653-63.
[cited by applicant]
Sadelain et al., “The basic principles of chimeric antigen receptor (CAR) design,” Cancer discovery (2013) 3 (4): 388-98. DOI: 10.1158/2159-8290.CD-12-0548.
[cited by applicant]
Schmittgen et al. “Analyzing real-time PCR data by the comparative C(T) method”,
[cited by applicant]
Sharma et al., “Efficient Sleeping Beauty DNA Transposition from DNA Minicircles,” Mol Ther Nuc Acids (2013) 2:e74, 1-10.
[cited by applicant]
Terakura et al., “Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells,” Gene Therapy (Oct. 26, 2011) 119(1), pp. 72-82.
[cited by applicant]
Treisman, R. “The SRE: a growth factor responsive transcriptional regulator. (PMID:2133110)”,
[cited by applicant]
Vigna et al., “Robust and Efficient Regulation of Transgene Expression in Vivo by Improved Tetracycline-Dependent Lentiviral Vectors,” Mol. Therapy (2002) 5(3):252-261.
[cited by applicant]
Vogt et al., “Doxycycline-regulated gene expression in the opportunisticfumigatus,” BMC Microbiol. (2005) 5(1):11 pages.
[cited by applicant]
Wang et al., “Phenotypic and Functional Attributes of Lentivirus Modified CD19-specific Human CD8+ Central Memory Tcells Manufactured at Clinical Scale,” J Immunotherapy (2012) vol. 35, pp. 689-701.
[cited by applicant]
Wang et. al., “A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells”, Blood, vol. 118, No. 5, Aug. 4, 2011 (Aug. 4, 2011), pp. 1255-1263.
[cited by applicant]
Weill et al., “Translational control by changes in poly(A) tail length: recycling mRNAs,” Nature Structural & Molecular Biology (Jun. 2012) vol. 19, No. 6, pp. 577-585.
[cited by applicant]
Xu et al., “Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15,” Blood (Jun. 12, 2014) vol. 123, No. 24, pp. 3750-3759.
[cited by applicant]
Yant et al. “Mutational Analysis of the N-Terminal DNA-Binding Domain of Sleeping Beauty Transposase: Critical Residues for DNA Binding and Hyperactivity in Mammalian Cells,” Mol. Cell. Biol. (2004) 24(20):9239-9247.
[cited by applicant]
Ye et al., “Characterization of a silencer regulatory element in the human interferon-gamma promoter,” J. Biol. Chem., (Oct. 14, 1994) 269:25728-25734.
[cited by applicant]
Zambon et al., “Increased Expression of the Pro-Apoptotic Protein BIM: A Mechanism for cAMP/PKA-Induced Apoptosis of Immature T Cells,” J. Biol. Chem. (2011) 286(38):33260-33267.
[cited by applicant]
Extended European Search Report dated Jul. 17, 2017 in the European Patent Application No. 15776501.7, filed on Oct. 20, 2016.
[cited by applicant]
First Examination Report issued Mar. 1, 2017, received in New Zealand application 725081 filed Oct. 12, 2016.
[cited by applicant]
International Search Report mailed Jul. 10, 2015, received in PCT/US2015/24868 filed Apr. 8, 2015.
[cited by applicant]
Aalberse et al., “IgG4 breaking the rules,” Immunology (2002) 105:9-19.
[cited by applicant]
Aertgeerts et al., “Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein,” Journal of Biological Chemistry (2011) vol. 286, No. 21, p. 18756-18765, Bec♭ TEKCT…
[cited by applicant]
Berglund et al., “The epitope space of the human proteome,” Protein Science (2008) 17:606-613.
[cited by applicant]
Burns et al., 2010, A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas, Cancer Research, 70(8):3027-3033.
[cited by applicant]
Chen et al., 2013, Fusion protein linkers: property, design and functionality, Advanced Drug Delivery Reviews, 65(10):1357-1369.
[cited by applicant]
Chen et al., Jan. 2007, Generation of a transgenic mouse model with chondrocyte-specific and tamoxifen-inducible expression of cre recombinase, Genesis, 45:44-50.
[cited by applicant]
Chen et al., Sep. 15, 2005, NF-κ-B RelA phosphorylation regulates RelA acetylation, Molecular and Cellular Biology, 25(18):7966-7975.
[cited by applicant]
Circosta et al., “T Cell Receptor (TCR) Gene Transfer with Lentiviral Vectors Allows Efficient Redirection of Tumor Specificity in Naïve and Memory T Cells Without Prior Stimulation of Endogenous TCR,” Human Gene Therap…
[cited by applicant]
Courtney et al., 2018, TCR signaling: mechanisms of initiation and propagation, Trends in Biochemical Sciences, 43(2):108-123.
[cited by applicant]
Dolezal et al., 2000, ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in VL to VH orientation drives the formation of dimers, trimers, tetramers and…
[cited by applicant]
Edwards et al., 2003, The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS, J. Mol. Biol., 334:103-118.
[cited by applicant]
Frankel et al., “Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor,” Protein engineering (2000) vol. 13, No. 8, p. 575-581.
[cited by applicant]
Gagnon et al., “IL-6, in Synergy with IL-7 or IL-15, Stimulates TCR-Independent Proliferation and Functional Differentiation of CD8+ T Lymphocytes,” The Journal of Immunology (2008) 180:7958-7968.
[cited by applicant]
Ghatar et al., “Epitope Mapping of Human HER2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains,” Asian Pacific Journal of Cancer Prevention (2017) 18(11):3103-3110.
[cited by applicant]
Guedan et al., 2018, Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation, JCI Insight, 3(1):11-13.
[cited by applicant]
Guha et al., 2017, Frontline science: functionally impaired geriatric CAR-T cells rescued by increased α5β1 integrin expression, Journal of Leukocyte Biology, 102(2):201-208.
[cited by applicant]
Hege et al., 2017, Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer, Journal for Immunotherapy of Cancer, 5(1):1-14.
[cited by applicant]
Hudecek et al., Sep. 11, 2014, “The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity”, Cancer Immunology Research, 3(2):125-135.
[cited by applicant]
Jensen et al: “Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells”, Immunological Reviews., Special Issue, Dec. 13, 2013 vol. 257, No. 1; 127-144.
[cited by applicant]
Kanamori et al., A human-tissue type whose host is a human cell expression of plasminogen activator, Tissue Culture Research, 8(2):31-39, 1990.
[cited by applicant]
Kochenderfer et al., Accession No. ADM64594.1, FMC63-28Z receptor protein, Jun. 11, 2012, Genbank.
[cited by applicant]
Lin et al., 2009, Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses, Cytotherapy, 11(7):912-922.
[cited by applicant]
Liu et al., “IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells,” International Immunology (2007) vol. 19, No. 10, pp. 1213-1221.
[cited by applicant]
Lloyd et al., 2009, Modelling the human immune response: performance of a 10
[cited by applicant]
Long et al., 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nature Medicine, 21(6):581-590.
[cited by applicant]
Maeda et al., 1997, Engineering of functional chimeric protein G—Vargula Luciferase, Analytical Biochemistry, 249(2):147-152.
[cited by applicant]
Maus et al., 2013, T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer Immunology Research, 1(1):26-31.
[cited by applicant]
McKinlay et al., “Blood monocytes, myeloid dendritic cells and the cytokines interleukin (IL)-7 and IL-15 maintain human CD4+ T memory cells with mixed helper/regulatory function,” Immunology (2006) vol. 120, pp. 392-40…
[cited by applicant]
Muftuoglu et al., “CD161 Expression Identifies a Distinct Subset of Drug-Effluxing Viral-Specific Memory CD4+ T Cells That Preferentially Survive Cytotoxic Chemotherapy,” Blood (2012) 122(21):2024.
[cited by applicant]
Pakula et al., “Genetic analysis of protein stability and function,” Annual review of genetics (1989) vol. 23, No. 1, p. 289-310, c.305-306.
[cited by applicant]
Pelloquin et al., Dec. 1986, Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A, In Vitro Cell Dev Biol, 22(12):689-694.
[cited by applicant]
Richman et al., 2018, High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model, Cancer Immunology Research, 6(1):36-46.
[cited by applicant]
Robinsons et al., Jan. 1991, Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient, Drug Metab Dispos, 19(1):36-43.
[cited by applicant]
Sadelain et al., 2009, The promise and potential pitfalls of chimeric antigen receptors, Current Opinion in Immunology, 21:215-223.
[cited by applicant]
Schamel et al., 2019, The TCR is an allosterically regulated macromolecular machinery changing its conformation while working, Immunological Reviews, 291(1):8-25.
[cited by applicant]
Sengupta et al., “Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy,” BioMed Research International, (Aug. 27, 2014) vol. 2014, Article ID: 952128, pp. 1-8.
[cited by applicant]
Surh et al., “Homeostasis of memory T cells,” Immunological Reviews (2006) vol. 211, pp. 154-163.
[cited by applicant]
Teplyakov et al., 2014, Antibody modeling assessment II. Structures and models, Proteins: Structure, Function, and Bioinformatics, 82(8):1563-1582.
[cited by applicant]
Turtle et al., 2016, CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients, The Journal of Clinical Investigation, 126(6):2123-2138.
[cited by applicant]
Wilke et al., Apr. 27, 2012, Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling, Journal of Clinical Immunology, 32(5):1059-1070.
[cited by applicant]
Yang et al., Feb. 16, 2010, Functional interplay between acetylation and methylation of the RelA subunit of NF-κ-B, Molecular and Cellular Biology, 30(9):2170-2180.
[cited by applicant]
Zeng et al., “Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function,” JEM (Jan. 3, 2005) vol. 201, No. 1, pp. 139-148.
[cited by applicant]
Zheng, Changyu et al., “All Human EF1 Promoters Are Not Equal: Markedly Affect Gene Expression in Constructs from Different Sources,” International Journal of Medical Sciences (2014) 11(5):404-408.
[cited by applicant]
Hu et al., 2004, Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-κB activation and transformation in resistant JB6 cells, Carcinogenesis, 25(10):1991-2003.
[cited by applicant]
Majowicz et al., 2012, Murine CD4+ CD25-cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo, BMC Gastroenterology, 12:1-9.
[cited by applicant]
Badri et al., 2016, Optimization of radiation dosing schedules for proneural glioblastoma, J Math Bio, 72(5):1301-1336.
[cited by applicant]
Baylot et al., 2017, TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression, Results Probl Cell Differ, 64:255-261.
[cited by applicant]
Dolgikh et al., 2013, Heterologous expression of the extracellular domain of the HER2 receptor in bacteria, Scientific notes of St. Petersburg State Medical University named after. I. P. Pavlova, 20(4):70-73.
[cited by applicant]
Jost et al., 2013, Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2, Structure, 21(11):1979-1991.
[cited by applicant]
Kim et al, 2007, Efficiency of the Elongation Factor-1alpha Promoter in Mammalian Embryonic Stem Cells Using Lentiviral Gene Delivery Systems, Stem Cells and Development, 16:537-545.
[cited by applicant]
Olsen et al., Feb. 2013, Pitfalls in determining the cytokine profile of human T cells, Journal of Immunological Methods, 390:106-112.
[cited by applicant]
Pan et al., 2022, CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy, J Exp Clin Cancer Res, 41(1):119.
[cited by applicant]
Sentman, Aug. 1, 0213, Challenges of creating effective chimeric antigen receptors for cancer therapy, Immunotherapy 5(8):783-785.
[cited by applicant]